Figure 2.
Lenalidomide-induced PD-1+T cells display a specific transcriptomic profile. (A) Principal component analysis of PD-1– CD4 T cells (salmon symbols), PD-1+ CD4 T cells (green symbols), PD-1– CD8 T cells (blue symbols), and PD-1+ CD8 T cells (purple symbols), collected before and after 1 week of lenalidomide. For each cell subset, the vector directed from D0 to D7 is reported, starting from the centroid of the corresponding T-cell subset and colored accordingly. (B) Venn diagram of the Reactome pathways upregulated by lenalidomide in PD-1+ CD4 T cells and PD-1+ CD8 T cells. (C) Pie charts and ranked list of the top 15 biological processes activated by 1 week of lenalidomide treatment in PD-1+ CD4 (upper row) and PD-1+ CD8 T cells (lower row).

Lenalidomide-induced PD-1+T cells display a specific transcriptomic profile. (A) Principal component analysis of PD-1 CD4 T cells (salmon symbols), PD-1+ CD4 T cells (green symbols), PD-1 CD8 T cells (blue symbols), and PD-1+ CD8 T cells (purple symbols), collected before and after 1 week of lenalidomide. For each cell subset, the vector directed from D0 to D7 is reported, starting from the centroid of the corresponding T-cell subset and colored accordingly. (B) Venn diagram of the Reactome pathways upregulated by lenalidomide in PD-1+ CD4 T cells and PD-1+ CD8 T cells. (C) Pie charts and ranked list of the top 15 biological processes activated by 1 week of lenalidomide treatment in PD-1+ CD4 (upper row) and PD-1+ CD8 T cells (lower row).

Close Modal

or Create an Account

Close Modal
Close Modal